Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1583Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Phase 0 clinical trials in oncology new drug development

Gupta Umesh Chandra, Bhatia Sandeep, Garg Amit, Sharma Amit, Choudhary Vaibhav

Year : 2011| Volume: 2| Issue : 1 | Page no: 13-22

   This article has been cited by
1 Auricular Vagus Neuromodulation—A Systematic Review on Quality of Evidence and Clinical Effects
Nishant Verma,Jonah D. Mudge,Maïsha Kasole,Rex C. Chen,Stephan L. Blanz,James K. Trevathan,Eric G. Lovett,Justin C. Williams,Kip A. Ludwig
Frontiers in Neuroscience. 2021; 15
[Pubmed]  [Google Scholar] [DOI]
2 Pharmacological and Cellular Significance of Triazole-Surrogated Compounds
Naimish Kumar Verma,Dhananjoy Mondal,Smritilekha Bera
Current Organic Chemistry. 2020; 23(23): 2305
[Pubmed]  [Google Scholar] [DOI]
3 Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors
Visish M. Srinivasan,Chibawanye Ene,Brittany Parker Kerrigan,Frederick F. Lang
Neurosurgery Clinics of North America. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Lessons Learned from Two Decades of Anticancer Drugs
Zhichao Liu,Brian Delavan,Ruth Roberts,Weida Tong
Trends in Pharmacological Sciences. 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot,Lina Benajiba,Laura Faivre,Capucine Baldini,Lelia Haddag,Clement Bonnet,Christophe Massard,Frederic Bigot,Camille Bigenwald,Benjamin Verret,Zoé A. P. Thomas,Andrea Varga,Anas Gazzah,Antoine Hollebecque,David Ghez,Julien Lazarovici,Rastilav Balheda,Aurore Jeanson,Sophie Postel-Vinay,Alina Danu,Jean-Charles Soria,Xavier Paoletti,Vincent Ribrag
Investigational New Drugs. 2017;
[Pubmed]  [Google Scholar] [DOI]
6 Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?
Zhe Li,Qin Li,Jun Wu,Manyuan Wang,Junxian Yu
Molecules. 2016; 21(10): 1331
[Pubmed]  [Google Scholar] [DOI]
7 [18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment
Dmitry Soloviev,David Lewis,Davina Honess,Eric Aboagye
European Journal of Cancer. 2012; 48(4): 416
[Pubmed]  [Google Scholar] [DOI]


Read this article